Kinesins are a superfamily of motor proteins and often deregulated in different cancers. However, the mechanism of their deregulation has been poorly understood. Through examining kinesin gene family expression in estrogen receptor (ER)-positive breast cancer cells, we found that estrogen stimulation of cancer cell proliferation involves a concerted regulation of specific kinesins. Estrogen strongly induces expression of 19 kinesin genes such as Kif4A/4B, Kif5A/5B, Kif10, Kif11, Kif15, Kif18A/18B, Kif20A/20B, Kif21, Kif23, Kif24, Kif25, and KifC1, whereas suppresses the expression of seven others, including Kif1A, Kif1C, Kif7, and KifC3. Interestingly, the bromodomain protein ANCCA/ATAD2, previously shown to be an estrogen-induced chromatin regulator, plays a crucial role in the up-and downregulation of kinesins by estrogen. Its overexpression drives estrogen-independent upregulation of specific kinesins. Mechanistically, ANCCA (AAA nuclear coregulator cancer associated) mediates E2-dependent recruitment of E2F and MLL1 histone methyltransferase at kinesin gene promoters for gene activation-associated H3K4me3 methylation. Importantly, elevated levels of Kif4A, Kif15, Kif20A, and Kif23 correlate with that of ANCCA in the tumors and with poor relapse-free survival of patients with ER-positive breast cancer. Their knockdown strongly impeded proliferation and induced apoptosis of both tamoxifen-sensitive and resistant cancer cells. Together, the study reveals ANCCA as a key mediator of kinesin family deregulation in breast cancer and the crucial role of multiple kinesins in growth and survival of the tumor cells.
Introduction
The kinesin superfamily of motor proteins is encoded by more than 40 different genes in humans. They function by traveling unidirectionally along the microtubules for intracellular transport of molecules or organelles. Many of them such as Kif4A, Kif10/CENPE, and Kif11/Eg5 play important roles in cell division, particularly in different stages of mitosis and cytokinesis (1) . Several kinesins including Kif1A, Kif7, and KifC3 function primarily in nonmitotic processes such as protein complex or organelle movement and cellular signaling (2) (3) (4) (5) (6) . Overexpression of mitotic kinesins including KifC1, Kif10/CENPE, and Kif18A was found in several human cancers including breast cancer (7) (8) (9) (10) (11) . However, it is unclear whether other kinesins are aberrantly expressed in breast cancer and whether they play roles in the cancer cell proliferation and survival. Moreover, little is known about the mechanisms how the kinesin gene expression is deregulated in cancer cells.
The mitogenic effect of estrogen 17b-estradiol (E2) is primarily through its receptor estrogen receptor-a (ERa) to control gene expression. E2, through binding to ERs, plays pivotal roles in breast cancer development and progression. In cells, E2 treatment elicits changes in expression of hundreds of genes with the ones involved in cell-cycle progression, DNA synthesis and replication being the most robustly upregulated. Interestingly, estrogen also strongly represses many antiproliferative and proapoptotic genes. Although the majority of them are likely direct targets of ERa, many are regulated indirectly through estrogen control of other transcriptional regulators (12) (13) (14) (15) (16) (17) (18) .
ER-mediated transcriptional regulation involves assembly at target gene loci of chromatin regulators such as the p160/SRC coactivators, histone modifying or demodifying enzymes, and the ATP-dependent chromatin-remodeling proteins (15, 16, (19) (20) (21) . Different ER target genes may use different sets of specific chromatin regulators, which often act through transient and dynamic proteinprotein interactions (19, 22) . ANCCA (AAA nuclear coregulator cancer associated), a bromodomain containing, ATPase protein, was identified by us as a novel ERa coregulator and shown to play a critical function in mediating ER activation of CCND1, MYC, and E2F1 as well as E2-stimulated breast cancer cell proliferation (23) (24) (25) (26) (27) (28) . Importantly, ANCCA expression is strongly induced by E2 in ER-positive breast cancer cells. Its overexpression in tumors is highly associated with poor outcomes of patients with breast cancer (26) . Here, we examined the function of ANCCA in estrogen control of kinesin family gene expression. Our results revealed a pivotal role played by ANCCA in mediating both estrogen induction and repression of specific kinesins and demonstrated a critical function of ANCCA-activated kinesins in breast cancer cell proliferation and survival.
Materials and Methods
Cell culture, hormone treatment, and siRNA transfection MCF-7 and T-47D cells were obtained from the American Type Culture Collection (ATCC) and cultured in Dulbecco's Modified Eagle Medium (DMEM) or RPMI-1640 (Invitrogen), respectively, with 10% FBS (Gemini). For ligand treatment, cells were grown in phenol red-free medium supplemented with 10% charcoal-dextranstripped (cds) FBS (J R Scientific) for 3 days before being treated with E2 (at 10 À8 mol/L), 4-hydroxytamoxifen (Tam, at 10 À6 mol/L), or fulvestrant (at 10 À7 mol/L; all from Sigma-Aldrich) for indicated times. MCF-7 cells that ectopically express ANCCA were generated by transfection with pcD-HCMV-ANCCA (23, 28) , and stable transfectant cells were clonally isolated and expanded in the presence of G418 (300 mg/mL). Tamoxifen-resistant MCF-7 subline LCC2 cells (a kind gift from Dr. Robert Clarke at Georgetown University, Washington, DC) were cultured in DMEM þ 10% cds-FBS containing 10 À6 mol/L 4-hydroxytamoxifen. For siRNA transfection, cells were seeded at 2 Â 10 5 cells per well in 6-well plates in phenol red-free DMEM supplemented with 5% cds-FBS and transfected using DharmaFECT with siRNAs (Dharmacon) targeting ANCCA (29) , MLL1 (30) or Kif4A, Kif15, Kif20A, and Kif23 (Supplementary Materials and Methods).
Quantitative real-time PCR and immunoblot analysis
Total RNA was isolated and the cDNA was prepared, amplified, and detected in the presence of SYBR as previously (29) . The fluorescent values were collected and a melting curve analysis was performed. Fold difference was calculated as described previously (29) . Cell lysates were analyzed by immunoblotting with antibodies against specific kinesins, ANCCA, and other proteins. The PCR primers, details of cell lysates, and immnoblotting and antibodies are listed in the Supplementary Materials and methods.
Apoptosis and cell growth assays
For apoptosis, cells were transfected with siRNA on glass chamber slides and processed for TUNEL assay using the In Situ Cell Death Detection Kit (Roche) as previously described (26) . Random fields (10 fields per condition) of TUNEL-positive cells were counted and averaged. For cell growth, cells were seeded in 6-well plates at 1 Â 10 5 per well and treated as indicated. Total cell numbers were counted using a Coulter cell counter. The assays were performed in triplicates and the entire experiments were repeated three times.
Chromatin immunoprecipitation (ChIP) assay
ChIP was performed essentially as described previously (27, 28) with the following modifications. Cells were lysed and sonicated using Sonic Dismembrator 550 (Fisher Scientific). The crude chromatin solutions were first cleared with protein A beads (Invitrogen) that had been precoated with preimmune serum or normal immunoglobulin G (IgG) for 2 hours at 4 C. Then, the precleared solutions were incubated at 4 C overnight with antibodies against ANCCA (26), E2F1 (1:1 mixture of C-20 and KH-95; Santa Cruz Biotechnology), MLL (clone 9-12; Millipore), H3K4me3 and H3K27ac (ab8580 and ab4729, ChIP grade; both from Abcam), before precipitation with protein A beads that had been preblocked with bovine serum albumin (BSA) and sonicated salmon sperm DNA. The precipitated DNA was analyzed by realtime PCR with SYBR green on an iCycler instrument. Enrichment of genomic DNA was presented as the percentage recovery relative to the input. The primers are listed in the Supplementary Materials and Methods.
Analysis of kinesin expression in tumors for clinical outcome and ANCCA correlation and statistics Microarray data from GSE9195 (31) were downloaded from the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) website (http://www.ncbi.nlm.nih.gov/gds). The dataset consists of gene expression profiles of early stage, ER-positive breast cancer tumors that had received tamoxifen only as adjuvant treatment. Normalized probe set expression intensities were obtained using robust multi-array average for probe summarization and normalization as before (29) . Correlations of ANCCA/atad2 and kinesin expression were assessed by computing the Pearson correlation coefficient (r) and a two-tailed t test for significance. The Kaplan-Meier estimates were used to compute the survival curves. All above computations were conducted in R statistical package (http://www.r-project.org/). Kinesin expression and patient survival were also analyzed using an online survival analysis tool (32) . For the assays, the paired t test was performed as previously described (26) .
Results
Estrogen stimulation of breast cancer cell proliferation involves a concerted up-and downregulation of specific kinesin expression
We previously demonstrated that ANCCA is an estrogen responsive gene and controls the expression of cyclins and other genes important for cell proliferation and survival (23, 26) . This prompted us to investigate whether ANCCA plays any function in control of mitotic kinesins in ERpositive breast cancer cells. Thus, we first identified kinesins with expression regulated by E2 in estrogen-sensitive MCF7 cells. Remarkably, among the 38 kinesin genes with mRNA expression detected in MCF7 cells, E2 strongly stimulated the expression of a large number (19 out of 38, more than 2-fold in 12 hours and/or 24 hours of E2 treatment) of the detected kinesins, which include Kif2A, Kif3A, Kif3B, Kif4A, Kif4B, Kif5B, Kif10/CENPE, Kif11/EG5, Kif15, Kif16A, Kif18A, Kif18B, Kif20A, Kif20B, Kif21A, Kif23, Kif24, Kif25, and KifC1 (Fig. 1A) . In most cases, the induction can be observed by 12 hours of E2 stimulation. Except Kif2A, Kif5B, and Kif21A, most of them play important roles in mitosis and/or cytokinesis (1). Intriguingly, E2 also significantly repressed several kinesins, including Kif1A, Kif1C, Kif3C, Kif7, Kif13B, Kif16B, and KifC3. Notably, most of the repressed kinesins have primary functions in nonmitotic processes such as synaptic vesicle transport in neurons (Kif1A), integrin transport for cell migration (Kif1C), control of the Hedgehog (Hh)-Gli signaling (Kif7) and golgi positioning and integration with dynein (KifC3; refs. 2, 5, 33) .
Given the prominent function of E2-ER in promoting breast cancer cell proliferation, we focused our further analysis on mitotic kinesins. As shown before, ANCCA and its targets cyclin D1 and CDC6 are induced by E2 in MCF7 cells (Fig. 1B ). Western blotting with available antibodies confirmed the E2 induction of mitotic kinesin proteins of Kif4A, Kif11, Kif15, Kif20A, and Kif23 (Fig. 1B) . To examine whether the E2 regulation is through ERa, cells were treated with ERa pure antagonist fulvestrant. Indeed, when cells were treated simultaneously with E2 and fulvestrant, the kinesin induction by E2 was mostly suppressed ( Kif15, Kif20A, and Kif23 is through ERa. Similar results were obtained from another estrogen-sensitive cell T-47D (Fig. 1B, bottom) Data represent the mean AE SD of three independent experiments ( Ã , P < 0.01 for groups without E2 for each Kif gene; ÃÃ , P < 0.05 for groups with E2 for each Kif gene; paired t test).
ANCCA plays a crucial role in mediating E2 regulation of kinesins
To determine whether ANCCA mediates E2 control of the kinesins, we measured their expression in MCF7 cells with ANCCA suppressed by siRNA. As shown in Fig. 2A , ANCCA suppression markedly diminished E2 induction of most (18 out of 19) of the kinesins, which include Kif2A, Kif3A, Kif3B, Kif4A, Kif4B, Kif5B, Kif10/CENPE, Kif11/EG5, Kif15, Kif16A, Kif18A, Kif18B, Kif20A, Kif20B, Kif21A, Kif23, Kif25, and KifC1. More strikingly, for the seven kinesins that are repressed by E2, upon ANCCA silencing by siRNA, their repression by E2 was largely lost (except for Kif16B). Kif14 is the only one that was not significantly regulated by E2 but decreased by ANCCA suppression. Suppression of ANCCA by a different siRNA yielded essentially the same effects on E2-regulated kinesin mRNAs (data not shown). As expected, ANCCA suppression by the two siRNAs resulted in strong reduction . ChIP data represent the mean AE SD of three independent experiments ( Ã , P < 0.006 for groups between 0 and 3 hours of E2). C and D, MCF-7 cells were transfected with indicated siRNAs and treated with E2 for 3 hours before harvesting for ChIP with antibodies for E2F1, MLL1, and H3K4me3. ChIP data were analyzed as above and the normalized quantitative PCR values of ChIP DNA from cells treated with control siRNA and without E2 were set as 1. ChIP data represent the mean AE SD of three independent experiments ( ÃÃ , P < 0.01 for groups between siCont and siANCCA for each antibody). E and F, MCF-7 cells were treated with E2 and siRNA and analyzed, as in Fig. 2 for protein (E) and mRNA (F), except that mRNA analysis was performed with 24-hour E2 treatment ( ÃÃÃ , P < 0.01 for groups between siCont and siMLL1 for each Kif expression).
of protein levels of mitotic kinesin Kif4A, Kif11, Kif15, Kif20A, and Kif23 in the cancer cells (Fig. 2B) .
To further examine the function of ANCCA in control of kinesin expression, we analyzed whether elevated ANCCA promotes the kinesin expression. Strikingly, in the absence of E2, ectopic ANCCA was able to stimulate the mRNA expression of Kif4A, Kif11, Kif15, Kif20A, and Kif23 to the level almost equivalent to that induced by E2 in the vector control cells. Except Kif4A, E2 further stimulated their expression in the ANCCA-overexpressing cells (Fig.  3A) , suggesting that part of the ANCCA enhancement of kinesin expression is through ERa. Moreover, the ANCCA stimulatory effects can be observed on the kinesin proteins (Fig. 3B) . Thus, these results strongly suggest that chromatin-associated protein ANCCA is a key mediator of estrogencoordinated regulation of kinesin gene family in breast cancer cells.
E2 induction of kinesins involves the assembly and function of ANCCA, E2F, and their associated histone methyltransferase MLL
To examine the mechanism of ANCCA function in estrogen control of kinesin expression, we first performed ChIP assays for potential direct involvement of ANCCA. Indeed, marked ANCCA occupancy was observed at promoters of Kif4A, Kif15, Kif20A, and Kif23 upon E2 treatment for 1 or 3 hours (Fig. 4A and B and Supplementary Fig. S1 ). Inspection of the local sequences with ANCCA occupancy suggests binding sites for transcription factors E2Fs and c-Myc at the kinesin promoters. ChIP with anti-E2F1 antibody demonstrated a significant E2 induction of recruitment at the same locations, in support of our previous finding that ANCCA interacts with E2Fs and acts as a potent coactivator of E2Fs (27) . However, no consistent, E2-induced c-Myc binding was observed with a c-Myc antibody (data not shown). Notably, the ANCCA recruitment was associated with a significant increase of gene activation-linked histone marks such as H3K4me3 and H3K27ac, with H3K4me3 being highly elevated by E2. Because H3K4me3 is primarily deposited by histone methyltransferases such as MLL1, we next examined whether MLL1 is involved. Indeed, strong E2-induced recruitment of MLL1 at the kinesin gene promoters was observed. To determine the role of ANCCA in the E2-induced chromatin events, we performed ChIP with si-ANCCA knockdown cells. Remarkably, suppression of ANCCA strongly diminished E2-dependent recruitment of E2F1 and MLL1 at the kinesin promoters. Expectedly, MLL1-associated H3K4me3 level was also largely reduced ( Fig. 4C and D and Supplementary Fig. S1 ). Knockdown of MLL1 strongly mitigated E2 induction of the kinesin expression ( Fig. 4E and F) . Together, these results suggest that ANCCA plays an important role in mediating the assembly of E2F and MLL complexes, and H3K4me3 mark elevation at the kinesin gene promoters for E2 induction of their expression.
Kif4A, Kif15, Kif20A, and Kif23 are important for proliferation and survival of tamoxifen-sensitive and resistant breast cancer cells Several kinesins such as Kif11, Kif14, and Kif18A have recently been shown to be important for breast cancer cell proliferation. We, thus, focused on our analysis on the role of ANCCA-controlled Kif4A, Kif15, Kif20A, and Kif23 in cell growth and survival. Each of the four kinesins was knocked down by two different siRNAs. Each knockdown of Kif4A, Kif15, Kif20A, and Kif23 resulted in strong inhibition of E2-stimulated proliferation of tamoxifen-sensitive MCF7 cells (Fig. 5A) . Consistent with the marked reduction of (Fig. 5B and C) .
To further examine the function of ANCCA in control of kinesins, we performed the knockdowns in a tamoxifenresistant subline (LCC2) of MCF-7 cells (34-37). Comparing with the MCF-7 cells in which the kinesin and ANCCA expression was strongly inhibited by tamoxifen, LCC2 cells were essentially unresponsive to the inhibitory effect of tamoxifen on Kif4A, Kif15, Kif20A, and Kif23 (Fig. 6A) . Interestingly, ANCCA level was significantly higher in LCC2 cells than MCF-7 cells, especially when the cells were treated with tamoxifen. As expected, tamoxifen treatment alone did not alter LCC2 cell growth. Silencing each kinesin in LCC2 cells, however, markedly inhibited their hormone-independent proliferation ( Fig. 6B and Supplementary Fig. S2 , compare siCont-Tam and siKif-Tam). Importantly, the kinesin silencing also dramatically increased LCC2 cell sensitivity to tamoxifen inhibition (compare si-ContþTam and siKifþTam). Altogether, the results suggest that ANCCA-regulated kinesins play crucial roles in proliferation and survival of both tamoxifen-sensitive and resistant breast cancer cells.
High level of kinesins correlates with that of ANCCA and with poor outcome of ER-positive tumors
The above results that ANCCA-regulated kinesins play an important role in breast cancer cell growth and survival prompted us to examine the clinical significance of our experimental findings. In a dataset of gene expression profiles obtained from early stage, ER-positive breast cancer tumors that had received tamoxifen only as adjuvant treatment, high expression of Kif4A, Kif15, Kif20A, and Kif23 strongly correlated with poor relapse-free survival. Importantly, their expression also correlated significantly with the expression of ANCCA in the tumors (Fig. 7A and B and Supplementary  Fig. S3 ). To test further, the impact of high specific kinesin expression, we used an online survival analysis tool with a large database of breast cancer (1,413 ER-positive tumors) and found that high levels of each of the four kinesins tend to associate with poor prognosis (relapse-free survival; Fig. 7C and Supplementary Fig. S3 ). Together, these clinical data support the role of ANCCA as a key regulator of specific kinesins and indicate that their overexpression may drive breast cancer progression such as resistance to tamoxifen therapy.
Discussion
Little is known about the mechanism of kinesin family deregulation in human cancers. In this regard, this study made several unique and unexpected findings. with ER-positive tumors was determined using an online survival analysis tool as described in Materials and Methods. The P value for A and C was calculated by a log-rank test and the P value for B was obtained by a two-tailed t test.
many of the kinesins are upregulated by E2, at least seven are strongly downregulated by E2. Third, estrogen-regulated kinesins seem to play distinct and nonredundant function. Although many are mitotic regulators (Kif4A, Kif10, Kif11, Kif15, Kif18A, Kif20A, and Kif23), Kif3B is primarily involved in cell migration, and Kif24 is a centriolar kinesin and functions to remodel the local microtubules for cilia assembly (38) . Knockdown of individual mitotic kinesins such as Kif4A, Kif15, Kif20A, and Kif23 demonstrated that each of them is critical for cell proliferation or survival. Interestingly, kinesins repressed by E2, which include Kif1C, Kif3C, Kif7, Kif16B, and KifC3, are mostly nonmitotic kinesins (1) and they likely play different functions too. For instance, Kif1C is involved in stabilization of cellular trailing adhesions (33) . Kif1C gene is found mutated in a subset of metastatic, ERa-positive breast cancer (39) . Interestingly, Kif7 plays an important role in regulation of Hedgehog (Hh)-Gli signaling and its deletion contributes to the development of skin basal cell carcinoma (40) . One unexpected finding is that both E2-dependent induction and repression of kinesins involves the function of ANCCA. We reported previously that ANCCA acts as a novel coactivator of ERa (23) . The fact that ANCCA depletion results in derepression of specific kinesins strongly suggests that ANCCA also plays an important role in E2-dependent transcriptional repression. Although future study is needed to understand the underlying mechanism, it is conceivable that ANCCA, through its direct interaction with ERa, is recruited to the ER-repressed target genes and that recruited ANCCA, via its AAA type ATPase activity, may facilitate the assembly of repressive protein complexes such as the corepressor-HDAC, NRIP1/RIP140, or p300-CtBP (41, 42) . We focused our mechanistic analysis on the mitotic kinesins Kif4A, Kif15, Kif20A, and Kif23. Our ChIP analysis clearly showed that ANCCA directly occupies their promoter in the absence of hormone and that its occupancy is strongly increased upon E2 treatment. Thus, ANCCA may be involved in both estrogen-dependent and independent activation of the kinesins. This is consistent with recent findings that these mitotic kinesins are overexpressed in many types of cancers such as lung cancer, pancreatic cancer, and glioma that generally do not involve strong estrogen stimulation but also show ANCCA overexpression (41) (42) (43) (44) (45) . Interestingly, we showed here that ANCCA is required for E2F1 recruitment to the kinesin genes. We also found that ANCCA is required for E2-induced recruitment of MLL1 histone H3K4 methylase and the E2 induction of H3K4me3 mark at the kinesin gene promoter, as we demonstrated for androgen induction of EZH2 (46) . H3K4me3 mark is necessary for the RNA polymerase II preinitiation complex assembly (47) . Thus, together, our results suggest that upon estrogen stimulation, ANCCA occupancy at the kinesin genes is enhanced to facilitate the recruitment of E2F1 and MLL-mediated H3K4 methylation, which results in the assembly of Pol-II complex for transcriptional activation. How E2 stimulates the function of ANCCA at kinesin promoters is currently unknown. Although we were able to detect E2-induced robust recruitment of ERa to cyclin D1 enhancer and promoter, we were unable to detect any significant ERa recruitment to the ANCCA-occupied promoter regions of the kinesin genes examined (data not shown). It is possible that ERa acts through tethering to other transcription factor(s) (14, 21) or is recruited to an uncharacterized distal enhancer of the kinesin to facilitate ANCCA loading to the promoter through chromosomal looping. Future studies will be needed to determine the functional mechanism of ERa in the induction of specific kinesins.
Importantly, this study revealed that multiple kinesins including Kif4A, Kif15, Kif20A, and Kif23 are crucial for growth and survival of both tamoxifen-sensitive and resistant breast cancer cells. We also found that among the patients treated with tamoxifen, high levels of the four kinesins are strongly associated with poor recurrence-free survival. Thus, the results strongly suggest that kinesins such as Kif4A, Kif15, Kif20A, and Kif23 can have important values as both prognostic factors and new therapeutic targets for endocrine therapy-resistant breast cancer. However, kinesins may play similar cellular functions (1), which would necessitate simultaneous targeting of multiple kinesins for effective therapy. One alternative can be blocking MLL-mediated histone methylation, which is required for the kinesin gene activation. However, members of the MLL family are found mutated or deleted in multiple human cancers (48, 49) . Given ANCCA being a common activator of these kinesins, targeting ANCCA can be a more attractive option. With the small molecules targeting bromodomain proteins such as BRD4 are near clinical trial, development of inhibitors specifically targeting ANCCA bromodomain or its ATPase is highly desirable for effective treatment of aggressive breast cancer.
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